+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

mRNA Therapeutics CDMO Services Market Outlook 2026-2034: By Service, Stage, Customer

  • PDF Icon

    Report

  • 160 Pages
  • November 2026
  • Region: Global
  • OG Analysis
  • ID: 6291788
The mRNA Therapeutics CDMO Services Market is estimated at USD 16.2 billion in 2026 and is projected to reach USD 40.4 billion by 2034, growing at a CAGR of 12.1% during 2026-2034.

Market Overview

The mRNA Therapeutics CDMO Services Market covers contract development and manufacturing services dedicated to messenger ribonucleic acid therapeutics, spanning process development, analytical testing, formulation, and clinical or commercial supply. Developers need external manufacturing capacity for specific mRNA programs. Process development and formulation support transfer between stages.

Capacity fit and qualification affect contracts. Integrated services support sponsor relationships. Biopharma clusters shape demand. Customers compare execution capability, service continuity and clearly defined responsibilities. Pricing needs to reflect the resources and conditions involved in delivering the agreed scope. Contracts differ with operating conditions and customer requirements. Standard service packages and specialist assignments can require different staffing, planning and performance measures. Customers require relevant qualifications and consistent execution. Clear documentation and defined acceptance criteria help connect delivered work with the agreed service scope. Procurement evaluates staffing, scheduling and response capability. Reliable communications and clear reporting help customers manage service delivery alongside their own operations.

Key Takeaways

  • Demand drivers: Developers need external manufacturing capacity for specific mRNA programs. Recurring contracts and project assignments can follow different scheduling, resource and revenue patterns. Customers assess whether service capacity can meet the agreed scope under actual operating conditions.
  • Technology and performance: Process development and formulation support transfer between stages. Tools and information systems support delivery but do not replace the relevant practical expertise. Clear responsibilities, practical scheduling and dependable reporting help maintain continuity and support informed decisions about contract renewal or expansion.
  • Challenges and economics: Capacity fit and qualification affect contracts. Contract scope and response expectations need to be realistic for the conditions in which work is performed. Commercial demand depends on the scope of work required, customer operating needs and the availability of qualified service capacity.
  • Commercial opportunities: Integrated services support sponsor relationships. Specialist expertise can address work that customers cannot readily undertake themselves. Dependable execution and clear responsibilities support repeat engagements and longer-term relationships.
  • Geographic considerations: Biopharma clusters shape demand. Customer locations and local service capacity shape regional opportunities. Staffing, travel requirements and relevant operating rules affect how providers serve different markets. Customers compare execution capability, service continuity and clearly defined responsibilities.
  • Product and segment distinctions: Service coverage includes Development, Manufacturing, Formulation and Analysis and Other Support. Contracts differ with operating conditions and customer requirements. Standard service packages and specialist assignments can require different staffing, planning and performance measures.
  • Application and customer priorities: Stage categories include Preclinical, Clinical and Qualified Commercial. Customers require relevant qualifications and consistent execution. Clear documentation and defined acceptance criteria help connect delivered work with the agreed service scope.
  • Purchasing and delivery: Clients distinguish development activity from authorized commercial manufacturing. Procurement evaluates staffing, scheduling and response capability. Reliable communications and clear reporting help customers manage service delivery alongside their own operations.
  • Competitive positioning: Lonza, Catalent and Samsung Biologics are among the companies covered. The analysis distinguishes relevant product, technology and channel roles, with emphasis on application fit, supply capabilities and customer support.
  • Outlook priorities: The mrna therapeutics cdmo services outlook depends on the interaction of end-use demand, product qualification and commercially viable delivery. Integrated services support sponsor relationships. Biopharma clusters shape demand.

Competitive Landscape

The mrna therapeutics cdmo services competitive landscape includes Lonza, Catalent, Samsung Biologics and WuXi AppTec, alongside the other companies named in this report. Customers compare execution capability, service continuity and clearly defined responsibilities. Pricing needs to reflect the resources and conditions involved in delivering the agreed scope. Customers require relevant qualifications and consistent execution. Clear documentation and defined acceptance criteria help connect delivered work with the agreed service scope. Procurement evaluates staffing, scheduling and response capability. Reliable communications and clear reporting help customers manage service delivery alongside their own operations. The study compares relevant portfolios and routes to market, separating direct product provision from technology, distribution and service roles where applicable. Strategic assessment focuses on product development, application support and market access without treating every participant as a supplier of identical offerings.

Companies Mentioned

  • Lonza
  • Catalent
  • Samsung Biologics
  • WuXi AppTec
  • Thermo Fisher Scientific
  • Danaher
  • Recipharm
  • AGC Biologics
  • Curia
  • Resilience
  • Evonik Industries
  • Aldevron
  • Nitto Avecia
  • ST Pharm
  • Boehringer Ingelheim
  • Rentschler Biopharma
  • CordenPharma
  • Exothera
  • eTheRNA
  • Polypeptide Group

Market Segmentation: mRNA Therapeutics CDMO Services Market

By Service

  • Development
  • Manufacturing
  • Formulation
  • Analysis and Other Support

By Stage

  • Preclinical
  • Clinical
  • Qualified Commercial

By Customer

  • Biotech Developers
  • Pharmaceutical Companies
  • Other Qualified Sponsors

mRNA Therapeutics CDMO Services Market Analytics

The report employs rigorous tools, including Porter’s Five Forces, value chain mapping, and scenario-based modelling, to assess supply-demand dynamics. Cross-sector influences from parent, derived, and substitute markets are evaluated to identify risks and opportunities. Trade and pricing analytics provide an up-to-date view of international flows, including leading exporters, importers, and regional price trends.

Macroeconomic indicators, policy frameworks such as carbon pricing and energy security strategies, and evolving consumer behaviour are considered in forecasting scenarios. Recent deal flows, partnerships, and technology innovations are incorporated to assess their impact on future market performance.

mRNA Therapeutics CDMO Services Market Competitive Intelligence

The competitive landscape is mapped through proprietary frameworks, profiling leading companies with details on business models, product portfolios, financial performance, and strategic initiatives. Key developments such as mergers & acquisitions, technology collaborations, investment inflows, and regional expansions are analysed for their competitive impact. The report also identifies emerging players and innovative startups contributing to market disruption.

Regional insights highlight the most promising investment destinations, regulatory landscapes, and evolving partnerships across the report’s covered markets.

Countries Covered

  • North America - mRNA Therapeutics CDMO Services Market data and outlook to 2034
    • United States
    • Canada
    • Mexico

  • Europe - mRNA Therapeutics CDMO Services Market data and outlook to 2034
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • BeNeLux
    • Russia
    • Sweden

  • Asia-Pacific - mRNA Therapeutics CDMO Services Market data and outlook to 2034
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Malaysia
    • Vietnam

  • Middle East and Africa - mRNA Therapeutics CDMO Services Market data and outlook to 2034
    • Saudi Arabia
    • South Africa
    • Iran
    • UAE
    • Egypt

  • South and Central America - mRNA Therapeutics CDMO Services Market data and outlook to 2034
    • Brazil
    • Argentina
    • Chile
    • Peru
* We can include data and analysis of additional countries on demand.

Research Methodology

This study combines primary inputs from industry experts across the mRNA Therapeutics CDMO Services value chain with secondary data from associations, government publications, trade databases, and company disclosures. Proprietary modeling techniques, including data triangulation, statistical correlation, and scenario planning, are applied to deliver reliable market sizing and forecasting.

Key Questions Addressed

  • What are the current market size and outlook across the covered markets?
  • Which product and customer categories offer the most relevant opportunities?
  • How do supply conditions, pricing and competitive strategies affect market development?
  • Which risks and practical investment considerations should decision makers evaluate?

Your Key Takeaways from the mRNA Therapeutics CDMO Services Market Report

  • Global mRNA Therapeutics CDMO Services Market size and growth projections (CAGR), 2026-2034
  • Impact of geopolitical developments on mRNA Therapeutics CDMO Services trade, costs, and supply chains
  • mRNA Therapeutics CDMO Services Market size, share, and outlook across the 5 regions and country/subregional markets listed above, 2026-2034
  • mRNA Therapeutics CDMO Services Market size, CAGR, and market share of key products, applications, and end-user verticals, 2026-2034
  • Short- and long-term mRNA Therapeutics CDMO Services Market trends, drivers, restraints, and opportunities
  • Porter’s Five Forces analysis, technological developments, and mRNA Therapeutics CDMO Services supply chain analysis
  • mRNA Therapeutics CDMO Services trade analysis, mRNA Therapeutics CDMO Services Market price analysis, and mRNA Therapeutics CDMO Services supply/demand dynamics
  • Company profiles covering business overview, key strategies, financial information where available, and relevant products
  • Latest mRNA Therapeutics CDMO Services Market news and developments

This product will be delivered within 1-3 business days.

Table of Contents

1. mRNA Therapeutics CDMO Services Market - Executive Summary
1.1. Market Snapshot, 2026
1.2. Key Findings and Outlook, 2026-2034

2. mRNA Therapeutics CDMO Services Market - Market Scope and Research Methodology
2.1. Product and Service Definitions
2.2. Value Chain and Revenue Boundaries
2.3. Research Methodology and Forecast Assumptions

3. mRNA Therapeutics CDMO Services Market - Market Dynamics
3.1. Drivers, Trends and Opportunities
3.2. Constraints and Challenges

4. mRNA Therapeutics CDMO Services Market - Market Economics
4.1. Pricing and Procurement
4.2. Supply Chain and Relevant Policy Environment

5. mRNA Therapeutics CDMO Services Market - Market Size and Outlook, 2026-2034
5.1. Total Market Revenue
5.2. By Service
5.3. By Stage
5.4. By Customer

6. mRNA Therapeutics CDMO Services Market - North America Market Outlook
6.1. Regional Revenue and Forecast
6.2. By Service
6.3. By Stage
6.4. By Customer
6.5. Country Analysis

7. mRNA Therapeutics CDMO Services Market - Asia-Pacific Market Outlook
7.1. Regional Revenue and Forecast
7.2. By Service
7.3. By Stage
7.4. By Customer
7.5. Country Analysis

8. mRNA Therapeutics CDMO Services Market - Europe Market Outlook
8.1. Regional Revenue and Forecast
8.2. By Service
8.3. By Stage
8.4. By Customer
8.5. Country Analysis

9. mRNA Therapeutics CDMO Services Market - South and Central America Market Outlook
9.1. Regional Revenue and Forecast
9.2. By Service
9.3. By Stage
9.4. By Customer
9.5. Country Analysis

10. mRNA Therapeutics CDMO Services Market - Middle East and Africa Market Outlook
10.1. Regional Revenue and Forecast
10.2. By Service
10.3. By Stage
10.4. By Customer
10.5. Country Analysis

11. mRNA Therapeutics CDMO Services Market - Competitive Landscape
11.1. Companies Mentioned
11.2. Product and Service Portfolios
11.3. Supplier Positioning

12. mRNA Therapeutics CDMO Services Market - Strategic Developments and Outlook
12.1. Technology and Product Developments
12.2. Commercial Opportunities
12.3. Frequently Asked Questions

13. mRNA Therapeutics CDMO Services Market - Appendix
13.1. Definitions and Abbreviations
13.2. Sources and Forecast Assumptions

Companies Mentioned

  • Lonza
  • Catalent
  • Samsung Biologics
  • WuXi AppTec
  • Thermo Fisher Scientific
  • Danaher
  • Recipharm
  • AGC Biologics
  • Curia
  • Resilience
  • Evonik Industries
  • Aldevron
  • Nitto Avecia
  • ST Pharm
  • Boehringer Ingelheim
  • Rentschler Biopharma
  • CordenPharma
  • Exothera
  • eTheRNA
  • Polypeptide Group

Table Information